256 related articles for article (PubMed ID: 16024198)
1. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.
Koski A; Sistonen J; Ojanperä I; Gergov M; Vuori E; Sajantila A
Forensic Sci Int; 2006 May; 158(2-3):177-83. PubMed ID: 16024198
[TBL] [Abstract][Full Text] [Related]
2. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
[TBL] [Abstract][Full Text] [Related]
3. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
[TBL] [Abstract][Full Text] [Related]
4. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
[TBL] [Abstract][Full Text] [Related]
6. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.
Thieme D; Rolf B; Sachs H; Schmid D
Int J Legal Med; 2008 Mar; 122(2):149-55. PubMed ID: 17992535
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
[TBL] [Abstract][Full Text] [Related]
8. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
10. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon J
J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
[No Abstract] [Full Text] [Related]
11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
12. A fatal doxepin poisoning associated with a defective CYP2D6 genotype.
Koski A; Ojanperä I; Sistonen J; Vuori E; Sajantila A
Am J Forensic Med Pathol; 2007 Sep; 28(3):259-61. PubMed ID: 17721180
[TBL] [Abstract][Full Text] [Related]
13. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
[TBL] [Abstract][Full Text] [Related]
14. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
15. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.
Jiang ZP; Shu Y; Chen XP; Huang SL; Zhu RH; Wang W; He N; Zhou HH
Eur J Clin Pharmacol; 2002 May; 58(2):109-13. PubMed ID: 12012142
[TBL] [Abstract][Full Text] [Related]
16. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
17. [Genotyping of CYP2D6 and CYP2C19].
Slanar O; Drazd'áková M; Babiárová K; Pechandová K; Buzková H; Perlík F; Zima T
Cas Lek Cesk; 2007; 146(9):708-11. PubMed ID: 17966194
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
20. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
